PMV Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
PMVP$1.22-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets
| September 30,2026 (unaudited) | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $19,994 | $37,983 |
| Marketable securities, current | 82,566 | 74,960 |
| Prepaid expenses and other current assets | 2,334 | 2,284 |
| Total current assets | 104,894 | 115,227 |
| Property and equipment, net | 131 | 237 |
| Marketable securities, noncurrent | 5,955 | — |
| Right-of-use assets | 133 | 801 |
| Other assets | 291 | 297 |
| Total assets | $111,404 | $116,562 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,638 | $3,155 |
| Accrued expenses | 8,913 | 7,857 |
| Operating lease liabilities, current | 138 | 403 |
| Total current liabilities | 10,689 | 11,415 |
| Operating lease liabilities, noncurrent | — | 435 |
| Warrant liability | 43,607 | — |
| Total liabilities | 54,296 | 11,850 |
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value, 5,000,000 shares authorized at September 30, 2026 and December 31, 2025. No shares issued or outstanding at September 30, 2026 and December 31, 2025. | — | — |
| Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 75,534,742 and 53,331,766 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively. | — | — |
| Additional paid-in capital | 574,214 | 551,082 |
| Accumulated deficit | (516,950) | (446,454) |
| Accumulated other comprehensive (loss) income | (156) | 84 |
| Total stockholders’ equity | 57,108 | 104,712 |
| Total liabilities and stockholders’ equity | $111,404 | $116,562 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.